Zymeworks Presents New Phase 1 Data for ZW191 ADC at AACR
ZW191 delivered a confirmed objective response rate of 61% at 6.4–9.6 mg/kg in platinum‑resistant ovarian cancer, with a 57%...
Emerging Daraxonrasib Data for Pancreatic Cancer at AACR
Daraxonrasib delivered a 58% confirmed objective response rate in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (n=40;...
Miv-cel Shows Durable, Significant Benefit for Stiff Person
In a single-arm registrational Phase 2 trial (KYSA-8) in 26 patients with stiff person syndrome (SPS), a one-time infusion...
Study Initiated for 70% Faster Rapid Drug Screening
Intelligent Bio Solutions has initiated a validation study to cut the analysis time of its Intelligent Fingerprinting Drug Screening...
Powerful GABAB PAM Candidate Halts Primate Chronic Cough
In a non-human primate chronic cough model, Addex’s orally available GABAB positive allosteric modulator cut citric acid–induced cough frequency...
Prelude Therapeutics Prices $90M Underwritten Offering
Prelude Therapeutics priced a $90 million gross underwritten equity offering, issuing 18,018,014 shares at $4.44 and pre-funded warrants for...
Genetic Data Offers Breakthrough Hope for Pancreatic Cancer
ctDNA from 123 atebimetinib-treated patients showed rare emergent MAPK pathway alterations and minimal early molecular evolution, with resistance patterns...
Junshi Presents Emerging Results for Two Cancer Drug Studies
ORR signals dominated Junshi Biosciences’ AACR update: in first‑line metastatic colorectal cancer, JS207 plus XELOX produced a 71.0% objective...
CytoDyn Reveals New Leronlimab Data for mTNBC at AACR
In a retrospective cohort of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab exposure was associated with induction...
Trevi Therapeutics Closes Huge, Successful $173M Offering
Trevi Therapeutics has closed a public offering of 13.34 million shares at $13.00 per share for gross proceeds of...